Cargando…
Advances in Cardiovascular Care: How to Stimulate Innovation While Controlling Cost
There is increasing concern over the cost of pharmaceuticals. An approach to assessing the value of new pharmaceuticals compared with previous standards is cost-effectiveness analysis. Although cost-effectiveness analysis may not be able to directly answer societal questions about new drugs, it can...
Autores principales: | Weintraub, William S., Lee, Kelvin H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058936/ https://www.ncbi.nlm.nih.gov/pubmed/30062198 http://dx.doi.org/10.1016/j.jacbts.2017.12.001 |
Ejemplares similares
-
Needs-Based Innovation in Cardiovascular Medicine: The Stanford Biodesign Process
por: Schwartz, Jonathan G., et al.
Publicado: (2016) -
Leadership for Innovation in Healthcare: An Exploration
por: Weintraub, Philip, et al.
Publicado: (2018) -
CARD9-Mediated Signaling and Cardiovascular Diseases
por: Liu, Xuanyou, et al.
Publicado: (2022) -
Fallacies of Using the Win Ratio in Cardiovascular Trials: Challenges and Solutions
por: Ajufo, Ezimamaka, et al.
Publicado: (2023) -
Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012
por: Hwang, Thomas J., et al.
Publicado: (2016)